A Rapid Pharmacogenomic Assay to Detect Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.

Rationale: Standardized dosing of antitubercular drugs contributes to a substantial incidence of toxicities, inadequate treatment response, and relapse, in part due to variable drug concentrations achieved. SNPs in the NAT2 (N-acetyltransferase-2) gene explain the majority of interindividual pharmac...

Descripción completa

Detalles Bibliográficos
Publicado en:American Journal of Respiratory & Critical Care Medicine Vol. 204; no. 11; pp. 1317 - 1327
Autores principales: Verma, Renu, Patil, Sunita, Nan Zhang, Moreira, Flora M. F., Vitorio, Marize T., Santos, Andrea da S., Wallace, Ellen, Gnanashanmugam, Devasena, Persing, David H., Savic, Rada M., Croda, Julio, Andrews, Jason R., Zhang, Nan
Formato: research Journal Article
Publicado: Oxford University Press / USA 12/1/2021
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=154004548&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 154004548
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        1073449X
        1FG
      jtl: American Journal of Respiratory & Critical Care Medicine
      issn: 1073449X
      maglogo: N
    pubinfo:
      dt: 12/1/2021
      vid: 204
      iid: 11
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        154004548
        154004548
        NLM34375564
        154004548
        10.1164/rccm.202103-0564OC
        NLM34375564
        154004548
      ppf: 1317
      ppct: 10
      formats:
      tig:
        atl: A Rapid Pharmacogenomic Assay to Detect Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.
      aug:
        au:
          Verma, Renu
          Patil, Sunita
          Nan Zhang
          Moreira, Flora M. F.
          Vitorio, Marize T.
          Santos, Andrea da S.
          Wallace, Ellen
          Gnanashanmugam, Devasena
          Persing, David H.
          Savic, Rada M.
          Croda, Julio
          Andrews, Jason R.
          Zhang, Nan
        affil: Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California
      sug:
        subj:
          Tuberculosis, Pulmonary
          Antitubercular Agents Pharmacokinetics
          Transferases
          Isoniazid Pharmacokinetics
          Polymorphism, Genetic
          Polymerase Chain Reaction
          Algorithms
          Prospective Studies
          Genotype
          Tuberculosis, Pulmonary Metabolism
          Isoniazid Administration and Dosage
          Human
          Tuberculosis, Pulmonary Drug Therapy
          Predictive Value of Tests
          Pharmacogenetics
          Antitubercular Agents Administration and Dosage
          Comparative Studies
          Multicenter Studies
          Evaluation Research
          Validation Studies
      ab: Rationale: Standardized dosing of antitubercular drugs contributes to a substantial incidence of toxicities, inadequate treatment response, and relapse, in part due to variable drug concentrations achieved. SNPs in the NAT2 (N-acetyltransferase-2) gene explain the majority of interindividual pharmacokinetic variability of isoniazid (INH). However, an obstacle to implementing pharmacogenomic-guided dosing is the lack of a point-of-care assay. Objectives: To develop and test a NAT2 classification algorithm, validate its performance in predicting isoniazid clearance, and develop a prototype pharmacogenomic assay. Methods: We trained random forest models to predict NAT2 acetylation genotype from unphased SNP data using a global collection of 8,561 phased genomes. We enrolled 48 patients with pulmonary tuberculosis, performed sparse pharmacokinetic sampling, and tested the acetylator prediction algorithm accuracy against estimated INH clearance. We then developed a cartridge-based multiplex quantitative PCR assay on the GeneXpert platform and assessed its analytical sensitivity on whole blood samples from healthy individuals. Measurements and Main Results: With a 5-SNP model trained on two-thirds of the data (n = 5,738), out-of-sample acetylation genotype prediction accuracy on the remaining third (n = 2,823) was 100%. Among the 48 patients with tuberculosis, predicted acetylator types were 27 (56.2%) slow, 16 (33.3%) intermediate, and 5 (10.4%) rapid. INH clearance rates were lowest in predicted slow acetylators (median 14.5 L/h), moderate in intermediate acetylators (median 40.3 L/h), and highest in fast acetylators (median 53.0 L/h). The cartridge-based assay accurately detected all allele patterns directly from 25 μl of whole blood. Conclusions: An automated pharmacogenomic assay on a platform widely used globally for tuberculosis diagnosis could enable personalized dosing of INH.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N